DelveInsight’s, “Exosomes – Pipeline Insight, 2020” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Exosomes Understanding
Exosomes: Overview
Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells in culture and are created upon the fusion of the multivesicular body (MVB)—an intermediate endocytic compartment—with the plasma membrane. They are nano-sized vesicles capable of transferring DNAs, micro RNAs, non-coding RNAs, and lipids, with or without direct cell-to-cell contact, which represents a novel method of intracellular communication. MVB—a type of intraluminal vesicles (ILV’s)—buds inward into the endosomal lumen. Exosomes, produced in endosomal compartment of most eukaryotic cells, are released in the form of ILV’s in instances where the MVB fuses with the cell surface (the plasma membrane). The exosomes and other extracellular vesicles (EV’s) are present in tissues of the multicellular organisms, including biological fluids, such as blood, urine, and cerebrospinal fluid. They can also be released in vitro by the cultured cells into their growth medium.
Characteristics of Exosomes and Function
Exosomes are basically formed by the cellular endocytic pathway, which consists of three different stages:
• The plasma membrane invagination from the endocytic vesicles.
• The second stage is the inward building of endosomal membrane which gives rise to multivesicular bodies (MVB’s).
• The third and the last stage is when the MVB’s fuse with the plasma membrane and releases the vesicular contents, which in turn forms the exosomes.
The membrane proteins, which undergo the endosomal pathway, exhibit the same stages. Different types of lipidic molecules are known for their involvement in the exosome formation and release like phosphatidic acid and ceramides.
Composition
Due to its protein and lipid content, exosomes are special, providing an additional hint for their identification. Exosomes mainly include fusion and transport proteins (annexins and flotillin), heat shock proteins (HSP70), CDís proteins (CD9, CD81), and phospholipases and other lipid-related proteins. Due to its protein and lipid content, exosomes are special, providing an additional hint for their identification. Exosomes mainly include fusion and transport proteins (annexins and flotillin), heat shock proteins (HSP70), CDís proteins (CD9, CD81), and phospholipases and other lipid-related proteins. One can use all of these proteins as positive markers.
Biological functions of Exosomes
Exosomes are nano-sized EVs that have impressive physiological properties and emerge through the inward budding of the late endosomal membrane called multivesicular bodies (MVBs). As MVBs are fused with the plasma membrane, exosomes are released into the extracellular environment. They can either be taken up by target cells residing in the microenvironment or transported by biological fluids to distant sites. Exosomes have a small diameter range of 40–100 nm and a density of 1.13–1.19 g/ml in sucrose solution. They can be sedimented at 100,000 g by centrifugation. Also, exosome membranes are enriched with proteins from cholesterol, sphingomyelin, ceramide and lipid raft.
Exosomes Emerging Drugs Chapters
This segment of the Exosomes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Exosomes Emerging Drugs
• Neural exosomes (AB126): ArunA Biomedical
ArunA Biomedical’s proprietary neural exosomes cross the blood–brain barrier inherently and enable drugs and drug-combinations to naturally target cells and treat patients with a range of neurological disorders. Preclinical studies have demonstrated the therapeutic potential of these exosomes in multiple stroke models. These studies have shown that the exosomes enhance the nervous system’s self-repair mechanisms, translating into structural and functional benefits which may have improved survival, reduced infarct size, and improved mobility.
• ExoPr0: ReNeuron
Company’s CTX-derived exosomes candidate is currently in the preclinical stage and is being developed as a novel vector for delivering the third party biological drugs. ExoPr0 has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle in established preclinical disease models. The company intends to devote more significant resource to the application of ExoPr0 as a vector for delivering drugs.
• exoIL-12: Codiak Biosciences
exoIL-12 is a precision-engineered exosome therapeutic candidate expressing IL-12 on the surface of the exosome by molecular fusion to Codiak’s proprietary scaffold protein, PTGRFN. Developed via Codiak’s proprietary engEx platform, exoIL-12 is designed to target T-cells and Natural Killer cells and induce systemic anti-tumor immunity. Data from Codiak’s preclinical studies suggest that when administered intratumorally, exoIL-12 is retained in the tumor microenvironment, thus resulting in potent antitumor immunity and an improved toxicity profile compared to recombinant IL-12.
Further product details are provided in the report……..
Exosomes: Therapeutic Assessment
This segment of the report provides insights about the different Exosomes based drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Exosomes
There are approx. 50+ key companies which are developing the therapies for Exosomes. The companies which have their Exosomes drug candidates in the early stages, i.e. phase I include United Therapeutics Corporation.
• Phases
DelveInsight’s report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase II and Phase II/III)
• Mid-stage products (Phase II and Phase II/III)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intramuscular
• Intranasal
• Parenteral
• Intravenous
• Topical
• Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Vaccines
• Polymers
• Peptides
• Enzymes

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Exosomes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Exosomes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exosomes drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The therapies under development are focused on novel approaches to treat/improve Exosomes.
• Anjarium’s Hybridosome platform, coupled with the targeting technology and proprietary manufacturing methods, is a promising technology to overcome the delivery hurdles today’s most potent RNA therapeutic candidates face.
• Therapeutic Benefits: Exosomes are directly internalized by recipient cells, which prevent a multiplicity of potential concerns associated with the administration of living cells, and exosomes have therapeutic benefits, at least equivalent to their cellular source.
Exosomes Report Insights
• Exosomes Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Exosomes Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Exosomes drugs?
• How many Exosomes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Exosomes?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Exosomes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Exosomes and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Direct Biologics
• Codiak BioSciences
• ExoCyte Therapeutics
• Avalon GloboCare
• United Therapeutics Corporation
• Capricor Therapeutics
• Avalon GloboCare
• Azymus Therapeutics
• Versatope Therapeutics
• Lamellar Biomedical
• Celltrion
Key Products
• LAMELLASOME IPF-NA
• exoSTING
• ET-08
• AVA 201
• Unexisome
• CAP 2003
• exoIL 12
• AVA 203
• AZ 001
• VT 105